Pharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis
|
|
- Norma Ross
- 6 years ago
- Views:
Transcription
1 Pharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis Shaun E. Gleason, PharmD, MGS Associate Professor, Department of Clinical Pharmacy Director, Distance Degrees and Programs University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Disclosure: Past employee & current stockholder of Johnson & Johnson Family of Companies April 2018
2 Same as it ever was. Yeah, the twister comes Here comes the twister Same as it ever was. - Once in a Lifetime, Talking Heads 1 Egelund EF, Alsultan A and Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clin Pharm Ther 2015; 2015;98(4):
3 Learning Objectives At the end of this presentation, the learner will be able to: Describe the basic concepts of PK/PD, specifically: the fundamentals of PK the difference between PK and PD Describe the use of PK / PD principles in TB therapy, in particular, related to these in the use of: INH Rifamycins Aminoglycosides Discuss the use of Clinical PK / Therapeutic Drug Monitoring in TB in relation to: Optimizing efficacy Minimizing toxicity Patients needing it most 3
4 Intro to PK and PD Pharmacokinetics (PK): ADME: Study of the time course of Absorption, Distribution, Metabolism & Excretion. Clinical Pharmacokinetics The application of PK principles to the safe and effective therapeutic management of drugs in an individual patient aka Therapeutic Drug Monitoring (TDM) Pharmacodynamics (PD) Relationship between drug concentration at the site of action and the resulting effect DiPiro JT, Spruill WJ, Wade WE et al. Concepts in Clinical Pharmacokinetics, 5 th ed. Bethesda, MD : American Society of Health-System Pharmacists; p
5 KINETICS Pharmaco- Pharmaco- DYNAMICS Prescribed Dosing Regimen Drug at Site of Action Dosing & med errors Absorption Tissue & body fluid mass and volume Drug interactions Elimination Drug metabolism Adherence Genetic factors Drug interactions Tolerance Drug receptor status Effect of drug COMBOS Drug Effects DiPiro JT, Spruill WJ, Wade WE et al. Concepts in Clinical Pharmacokinetics, 5 th ed. Bethesda, MD : American Society of Health-System Pharmacists; p
6 Pharmacokinetics 101 Assume plasma/serum concs = concs at site Bioavailability / Absorption Drug properties Pt factors Drug / food interactions Vol of Dist (Vd): dosing proportional to Vd Drug properties Pt factors DiPiro JT, Spruill WJ, Wade WE et al. Concepts in Clinical Pharmacokinetics, 5 th ed. Bethesda, MD : American Society of Health-System Pharmacists; p
7 Pharmacokinetics 101 Clearance (volume / time): measure of removal of drug from plasma Blood flow C in Organs of Elim n (Kidneys, Liver) Elimination C out Blood flow DiPiro JT, Spruill WJ, Wade WE et al. Concepts in Clinical Pharmacokinetics, 5 th ed. Bethesda, MD : American Society of Health-System Pharmacists; p
8 Pharmacokinetics 101 Half-life (T 1/2 ): Time for concs to decrease by 50% T 1/2 is independent of dose and concentration Regardless of conc, drug gone after 5-7 T 1/2 s A proportionality constant, dependent on Cl & Vd T 1/2 = x Vd Clearance / Elimination: related to volume and T 1/2 of drug T 1/2 = 0.693/ K e K e = Cl / Vd Cl = K e x Vd K e = ln C 1 /C 2 / T DiPiro JT, Spruill WJ, Wade WE et al. Concepts in Clinical Pharmacokinetics, 5 th ed. Bethesda, MD : 8 American Society of Health-System Pharmacists; 2010; p Cl
9 PK Case AB PK Parameter AB is a 42 yo WM being treated for TB with SM 1000mg (~13 mg/kg) IV QM-F. Other meds: RIF/EMB/PZA AB has a h/o CHF, ESLD, and DM. Wt = 75 kg, Ht = 65 in. Labs: BUN = 15, SCr = 1.1 SM MIC = 8 mcg/ml Serum SM concs reveal: Calculated Cmax = 22 mcg/ml (nl=35-45 mcg/ml) Serum T 1/2 = 5.2 hrs (nl SM T 1/2 = 2-3 hrs) 9
10 Pt Case AB Question What is the most likely cause of AB s serum SM concentrations and PK parameters being not quite normal? a. Renal dysfunction b. Large volume of distribution c. Reduced absorption of the streptomycin d. Drug interaction affecting metabolism of SM 10
11 Use of PK / PD Principles in TB Therapy 11
12 PK/ PD Response Parameters Time > MIC More frequent dosing to maintain time above the MIC INH, Ethionamide AUC > MIC Cmax / MIC Concentration-dependent Best given as large (usually daily) doses Aim for ratio of at least AMG s, FQ s, Rifamycins 12
13 PD: Response Parameters Conc Cmax AUC > MIC MIC Cmax = 9 mcg/ml MIC = 3 mcg/ml Cmax/MIC = 3 T > MIC = 8h AUC (mcg * h/ml) 13
14 Ethionamide Cmax MIC T > MIC = ~ 4h 14
15 INH Concs. by Acetylator status Conc. (mg/l) MIC SLOW = t ½ 3.35 hr, AUC 54.9 mcg*hr/ml Int.= t½ 1.56 hr, AUC 35.7 mcg*hr/ml FAST = t ½ 1 hr, AUC 25.0 mcg*hr/ml Time / Hours Parkin DP, Vandenplas S, Botha FJH, et al. Trimodality of Isoniazid: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med. 1997;155 (5):
16 KINETICS Pharmaco- Pharmaco- DYNAMICS Prescribed Dosing Regimen Dosing & med errors Absorption Tissue & body fluid mass and volume Drug interactions Elimination Drug metabolism Adherence Drug at Site of Action Genetic factors Drug interactions Tolerance Pt factors Drug receptor status Effect of drug COMBOS Drug Effects DiPiro JT, Spruill WJ, Wade WE et al. Concepts in Clinical Pharmacokinetics, 5 th ed. Bethesda, MD : American Society of Health-System Pharmacists; p
17 PD: Impact of PK Mismatch PK Mismatch Short T 1/2 drug + long T ½ drug Resistance or Failure Reports in TB Strong relationship between low INH and therapeutic failure/relapse in QW INH/RPT 1 No effect of mismatch 2 : INH and rifampin Important in HIV co-infection 3, 4 1. Weiner M, Burman W, Vernon A, et al. Am J Respir Crit Care Med. 2003; 167: Srivastava S et al. Antimicrob. Agents Chemother. 2011; 55: Peloquin CA. Antimicrob. Agents Chemother. 2012; 56(3): Egelund EF and Peloquin CA. Clin Infect Dis. 2012; 55:
18 PK Mismatch PD Response: Low INH with Rifampin & Rifapentine PK Param INH Med AUC BIW I/Rif FAILURE / Relapse (n=16) Cure (n=33) PValue Weiner M et al. Am J Respir Crit Care Med. 2003; 167: QW I/Rpt FAILURE/ relapse (n=22) Cure (n=49) P Value Med Cmax Med T1/ Rifamycin Med AUC Med Cmax Med T1/
19 Reduced Concentrations in HIV+ Rifampin HIV+ Hlthy vol Ethambutol HIV+ Hlthy vol Perlman DC et al for the ACTG 309 Team. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with TB. Clin Infect Dis 2005; 41:
20 EFFECT: RFB & INH AUC in HIV+ ARR Failures / Relapse N=5; Acquired rifamycin resistance (ARR) N=90; no ARR failure or relapse Weiner M et al. Association between acquired rifamycin resistance and the pharmacokinetics of 20 rifabutin and isoniazid among patients with HIV and tuberculosis.clin Infect Dis 2005; 40:
21 ID (TB): Usual PK/PD Response Parameters Time > MIC More frequent dosing to maintain time above the MIC INH, Ethionamide AUC > MIC Cmax / MIC Concentration-dependent Best given as large (daily, intermittent) doses Aim for Cmax to MIC ratio of at least (AMG s) AMG s, FQ s, Rifamycins 21
22 PD: Response Parameters Cmax AUC > MIC MIC Cmax = 9 mcg/ml MIC = 3 mcg/ml Cmax/MIC = 3 T > MIC = 8h AUC (mcg * h/ml) 22
23 Streptomycin mcg/ml Cmax MIC Cmax = 64 mcg/ml MIC = 8 mcg/ml Cmax/ MIC = 8 23
24 Rifampin 600 mg in Humans Cumulative % Culture Negative Month H 300 R 600 Z 2 S 2 QD H 300 R 600 Z 2 E 2 QD Other doses: S750mg, Z 35mgkg, E 25mg/kg, R 450 mg if <50kg British Thoracic Association. A controlled trial of six months of chemotherapy in pulmonary tuberculosis. Br J Dis Chest 1981;75:
25 Rifampin 1200mg in Humans Cumulative % Culture Negative Month H 900 R 1200 S 2 QD H 900 R 1200 S 2 QOD* Other doses: S 1000 mg QD* both regimens Kreis B, Pretet S. Two three-month treatment regimens for pulmonary tuberculosis. Bull Int Union Tuber 1976; 51:
26 Rifampin 600mg vs 1200mg Cumulative % Culture Negative Month H 300 R 600 Z 2 S 2 QD H 900 R 1200 S 2 QD Other doses: S 750mg in first, 1000 mg QD in second Note: RIF dose response also seen with INH 300mg + RIF 450mg, 600mg, or 750mg QD (Long et al) Br J Dis Chest 1981; 75: Kreis B et al. Bull Int Union Tuber 1976; 51: Long MW, Snider DE, Farer LS. Am Rev Resp Dis. 1979; 119:
27 Rifampin 1200mg Flu-like syndrome: NOT reported by Kreis et al More related to intermittent therapy May be best to optimize current regimens Kreis B et al. Bull Int Union Tuber 1976; 51: Egelund EF, Alsultan A and Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clin Pharm Ther. 2015; 2015;98(4): Peloquin C. What is the right dose of rifampin? Int J Tuberc Lung Dis 2003; 7:
28 Pt Case: AB Dose Optimization Recall that AB had an SM Cmax of 22 mcg/ml and an SM MIC of 8 mcg/ml. AB also had an extended serum T1/2 of 5.2 hrs. We are concerned about the effectiveness of this SM dose because of which dosing principle? a) The Time > MIC is not optimal b) The Cmax / MIC is not optimal c) The AUC > MIC is not optimal 28
29 Use of Therapeutic Drug Monitoring (TDM) in TB 29
30 Therapeutic Drug Monitoring (TDM)* GOAL: Optimization of therapy for individual pt: Maximize efficacy and/or Minimize toxicity Use with other clinical data Most valuable when *aka Clinical Pharmacokinetics Wide intersubject variation Therapeutic concs toxic concs Serum concs surrogate for concs at site of action DiPiro JT, Spruill WJ, Wade WE et al. Concepts in Clinical Pharmacokinetics, 5 th ed. Bethesda, MD : American Society of Health-System Pharmacists; p
31 TDM: What it s really about NOT necessarily normal ranges Rather, individualized goals for each pt. Goals should consider: Efficacy needs Toxicity acceptance Once drug is chosen: Determine desired conc. Try to achieve! Therapeutic concentrations vary by patient Jelliffe R. Goal-oriented, model-based regimens: setting individualized goals for each patient. Ther Drug Mon 2000; 22(3):
32 100 Response * Probability ( % ) 50 Tx Range Potential ex: Cycloserine Drug Concentration ( mcg / ml ) Toxicity Adapted from: Evans W in General Principles of Pharmacokinetic Michael E Burton, Leslie M Shaw, Jerome J Schentag, William E Evans. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring. 4 th Edition
33 TDM with TB Drugs May be more important than adherence(??) 1 Meta-analysis: PK variability to single drug associated with failure & acquired resistance Need at least 60% non-adherence to impact outcomes Useful for 2-4 Slow to respond to treatment Drug-resistant TB Risk of drug-drug interactions Concurrent disease (HIV, DM, Hep/renal dysfunction) 1. Pasipanodya JG et al. Clin Infect. Dis. 2012; 55: Peloquin CA. Use of Therapeutic Drug Monitoring in Tuberculosis Patients. Chest 2004; 126: Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis. Drugs 2002; 62: Srivastava S et al; Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Resp J. 2013; 42:
34 PD: Drug tolerance Aminoglycoside Toxicity AK, SM, KM Regimens in TB and MAC: mg/kg IV 5x/wk Cmax = mcg/ml mg/kg IV TIW Cmax = mcg/ml Dose or serum concentrations did not predict: Hearing loss Vestibular toxicity Nephrotoxicity Conclusions Older pts minimize duration Larger pts ok to go >1000mg Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clinical Infectious Diseases. 2004; 38:
35 Drug TDM: How to guide 1-2 hr postdose 6 hr postdose INH X X Rifampin X X Ethambutol X X 10 hr post-dose Pyrazinamide X X AK, SM, CM, KM* (*or 30 min /p infusion) X X X (ideally) Levo & Moxi X X Cycloserine X X PAS X X Ethionamide X X Two or more time-points ideal (better PK info) If can only do one, check the Cmax ( peak ; first one) Consult an expert Don t be afraid of the info! Dose max is not necessarily the max in your patient 35
36 Recall: Back to AB: AB is a 42 yo WM being treated for TB with: SM 1000mg (~13 mg/kg) IV QM-F, RIF 600 mg po QD, EMB 800 mg po QD, PZA 1000 mg po QD. AB has a h/o CHF and DM. 36
37 AB - Regimen Questions: Which other med(s) might we be most concerned about not being optimized in AB (and why)? a) Rifampin b) Rifampin and PZA c) Rifampin and Ethambutol 37
38 AB - Regimen Questions (cont d): Rifampin serum concs. reveal (nl = 8-24 mcg/ml): 2 hr: 6 mcg/ml 6 hr: 3 mcg/ml Without doing PK calculations, what might be a better new RIF dose (and why)? a) RIF 600 mg IV QD b) RIF 600 mg PO BID c) RIF 900 mg PO QD 38
39 Conclusions Overview of PK/PD PK time course ADME; PD - effect at site Therapeutic Drug Monitoring (TDM) PK / PD in TB INH time-dependent RIF, AMGs concentration dependent PK mismatch important, especially with INH and long half-life rifamycins (RFB and RPT) Use of TDM in TB Important in TB tx Offers individualized tx Efficacy / Toxicity Drug Interactions / Concurrent clinical problems 39
40 With an understanding of PK/PD and TDM, let s aim to make TB treatment NOT the same as it ever was. Egelund EF, Alsultan A and Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clin Pharm Ther. 2015; 2015;98(4):
41 Questions? 41
42 References British Thoracic Association. A controlled trial of six months of chemotherapy in pulmonary tuberculosis. Br J Dis Chest 1981;75: DiPiro JT, Spruill WJ, Wade WE et al. Concepts in Clinical Pharmacokinetics, 5 th ed. Bethesda, MD: American Society of Health-System Pharmacists; p1-44 Egelund EF and Peloquin CA. Pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance. Clin Infect Dis. 2012; 55: Egelund EF, Alsultan A and Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clin Pharm Ther. 2015; 2015;98(4): Jelliffe R. Goal-oriented, model-based regimens: setting individualized goals for each patient. Ther Drug Mon 2000; 22(3): Kreis B, Pretet S. Two three-month treatment regimens for pulmonary tuberculosis. Bull Int Union Tuber 1976; 51: Long MW, Snider DE, Farer LS. US publich health service cooperative trial of three rifampinisoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Resp Dis. 1979; 119: Li J et al. Use of Therapeutic Drug Monitoring in Tuberculosis Patients. Chest 2004; 126: McCormack JP, Jewesson PJ. A critical re-evaluation of the therapeutic range of aminoglycosides. Clinical Infectious Diseases. 1992; 14: Parkin DP, Vandenplas S, Botha FJH, et al. Trimodality of Isoniazid: phenotype and genotype in patients with tuberculosis.. Am J Respir Crit Care Med. 1997;155 (5): Pasipanodya JG et al. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infec. Dis ; 55:
43 References - continued Peloquin CA. Pharmacokinetic mismatch of tuberculosis drugs. Antimicrob. Agents Chemother. 2012; 56(3): Peloquin C. What is the right dose of rifampin? Int J Tuberc Lung Dis 2003; 7: 3-5. Peloquin CA. Use of Therapeutic Drug Monitoring in Tuberculosis Patients Chest 2004; 126: Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis. Drugs 2002; 62: Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clinical Infectious Diseases. 2004; 38: Perlman DC et al for the ACTG 309 Team. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with TB. Clin Infect Dis 2005; 41: Srivastava S et al. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis resistance but to better antimicrobbial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob. Agents Chemother. 2011; 55: Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T and the Tuberculosis Trials Consortium. Am J Respir Crit Care Med. 2003; 167: Weiner M et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.clin Infect Dis 2005; 40: Weiner M, Burman W, Vernon A, et al. Low Isoniazid Concentration Associated with Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine. Am J Respir Crit Care 43 Med. 2003; 167:
Pharmacology and Pharmacokinetics of TB Drugs Part I
Pharmacology and Pharmacokinetics of TB Drugs Part I Charles A. Peloquin, Pharm. D. Professor, and Director Infectious Disease Pharmacokinetics Laboratory College of Pharmacy and The Emerging Pathogens
More informationTreatment of Tuberculosis
TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose
More informationWhat is drug resistance? Musings of a clinician
What is drug resistance? Musings of a clinician William Burman MD Denver Public Health Tuberculosis Trials Consortium Financial disclosures Tibotec (developer of TMC207 and several antiretroviral drugs)
More informationTherapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation
Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation Randall Reves, MD, MSc TB Consultant Professor of Medicine and
More informationTreatment of Tuberculosis Therapeutic Drug Monitoring
Treatment of Tuberculosis Therapeutic Drug Monitoring 2nd European Advanced Course in Clinical Tuberculosis Dr. JWC Alffenaar, clinical pharmacologist Dept Clinical Pharmacy & Pharmacology University Medical
More informationOverview. Therapeutic Window. Does drug concentration matter? Treatment of Tuberculosis Therapeutic Drug Monitoring
Treatment of Tuberculosis Therapeutic Drug Monitoring 2nd European Advanced Course in Clinical Tuberculosis Dr. JWC Alffenaar, clinical pharmacologist Dept Clinical Pharmacy & Pharmacology University Medical
More informationOutline 8/2/2013. PK/PD PK/PD first-line drug กก PK/PD กก
Pharmacokinetic and pharmacodynamic of anti- tuberculosis drugs Outline PK/PD PK/PD first-line drug กก PK/PD กก Concentration vs time in tissue and other body fluids Pharmacologic or toxicologic effect
More informationOvercoming the Challenges in Access to TB Drugs for Children
Overcoming the Challenges in Access to TB Drugs for Children Gregory L. Kearns, PharmD, PhD Professor of Pediatrics and Pharmacology, University of Missouri Marion Merrell Dow / Missouri Chair in Pediatric
More informationTreatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationTB Updates for the Physician Rochester, Minnesota June 19, 2009
TB Updates for the Physician Rochester, Minnesota June 19, 2009 Recent Findings & Activities of the Tuberculosis Trials Consortium (TBTC) Bill Burman Denver TBTC Unit & Denver Public Health Recent findings
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationDRUG SIDE EFFECTS AND TOXICITY
DRUG SIDE EFFECTS AND TOXICITY Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Objectives After participating in this lecture,
More informationNEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence
More informationDrug Side Effects and Toxicity
Drug Side Effects and Toxicity Gwen A. Huitt, MD MS Professor, Division of Mycobacterial and Respiratory Infections National Jewish Health Disclosures None Toxicity Nausea and vomiting Any Drug Can Cause
More informationPharmacokinetics and doses of antituberculosis drugs in children
Pharmacokinetics and doses of antituberculosis drugs in children HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University Declarations I have no conflict of interest
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received
More informationMarcos Burgos, MD has the following disclosures to make:
Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures
More informationSubstance Abuse and Tuberculosis Springfield, IL April 27, 2011
Substance Abuse and Tuberculosis Springfield, IL April 27, 2011 Co-morbidities in Substance Abuse that Impact Managing TB Lisa Armitige, MD, PhD April 27, 2011 Lisa Armitige, MD, PhD has the following
More informationPZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data. Tawanda Gumbo
PZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data Tawanda Gumbo Office of Global Health University of Texas Southwestern Medical Center, Dallas, Texas The team: this work
More informationNon-rifampin rifamycins in TB/HIV
Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic Rifamycins for TB Inhibit bacterial DNA-dependent
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationStandard TB Treatment
Standard TB Treatment Chris Keh, MD TB Controller, TB Prevention and Control Program, San Francisco Department of Public Health Assistant Clinical Professor, Division of Infectious Diseases, University
More informationTreatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More information2401 Gillham Road Kansas City, Missouri Phone (816)
2401 Gillham Road Kansas City, Missouri 64108 Phone (816) 234-3000 www.childrens-mercy.org Children s Mercy Hospitals and Clinics Division of Clinical Pharmacology and Medical Toxicology CPMT Project.:
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment
More informationHot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
More informationTherapeutic drug monitoring (TDM) is the process. Use of Therapeutic Drug Monitoring for Multidrug-Resistant Tuberculosis Patients*
Use of Therapeutic Drug Monitoring for Multidrug-Resistant Tuberculosis Patients* Jiehui Li, MBBS, MS; Joseph N. Burzynski, MD, MPH; Yi-An Lee, MPH; Debra Berg, MD; Cynthia R. Driver, RN, MPH; Renee Ridzon,
More informationWhat He Said: Rifampin versus Rifapentine
What He Said: Rifampin versus Rifapentine Charles A. Peloquin, Pharm.D. Director Infectious Disease Pharmacokinetics Laboratory Professor, College of Pharmacy & The Emerging Pathogens Institute University
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationWeekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis
Weekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis Ian M. Rosenthal, Kathy Williams, Sandeep Tyagi, Andrew A. Vernon, Charles A. Peloquin, William R. Bishai,
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationPotent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis
Potent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis Ian M. Rosenthal, Kathy Williams, Sandeep Tyagi, Charles A. Peloquin, Andrew A. Vernon, William R. Bishai, Jacques H. Grosset,
More informationThe authors assessed drug susceptibility patterns
Drug Resistance Among Tuberculosis Patients, 1991 and 1992 New York City, CYNTHIA R. DRIVER, RN, MPH THOMAS R. FRIEDEN, MD, MPH ALAN B. BLOCH, MD, MPH IDA M. ONORATO, MD All the authors are with the Division
More informationTB in the Correctional Setting Florence, Arizona October 7, 2014
TB in the Correctional Setting Florence, Arizona October 7, 2014 Diagnosis and Treatment of TB Disease Renuka Khurana, MBBS, MPH October 7, 2014 Renuka Khurana, MSSB, MPH has the following disclosures
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationPharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in patients with tuberculosis
Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in patients with tuberculosis Julie B Prahl, MD, PhD International Reference Laboratory of Mycobacteriology, Diagnostics and Infection Control
More informationPredicting outcomes and drug resistance with standardised treatment of active tuberculosis
Eur Respir J 21; 36: 87 877 DOI: 1.1183/931936.15179 CopyrightßERS 21 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis O. Oxlade*,#, K. Schwartzman*,#, M. Pai*,#,
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationTreatment of Tuberculosis
Treatment of Tuberculosis, 1940 s Treatment of Tuberculosis ATS/CDC/IDSA Joint Statement 2003 Saskatchewan Lung Association Outline, 2012 Treatment of Tuberculosis Principles of treatment of tuberculosis
More informationANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO
ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept
More informationTB Expert Network Conference 9/26/2008
TB Expert Network Conference 9/26/2008 Case 1-KT1 35 y/o AA male with a history of HIV since 2002. Presented in July 2007 to a hospital in Orlando, FL with 1 month history of productive cough, fevers and
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationTBTC research update: are we ready for 3 month treatment? 2009 TBTC Recompetition. NTCA presentation outline
TBTC research update: are we ready for 3 month treatment? Stefan Goldberg, MD Project officer, TBTC Studies 27, 28, 29 Tuberculosis Trials Consortium (TBTC) CDC Division of TB Elimination NTCA breakout
More informationThe clinical pharmacology and drug interactions of bedaquiline
7 TH FIDSSA 2017 The clinical pharmacology and drug interactions of bedaquiline Helen McIlleron Division of Clinical Pharmacology University of Cape Town 20 years 2 drugs conditional approval based on
More informationPresentations and Publications of the Tuberculosis Trials Consortium (as of August 15, 2010)
1 Presentations and Publications of the Tuberculosis Trials Consortium (as of August 15, 2010) I. Publications 1999 Vernon A, Burman W, Benator D, Khan A, Bozeman L for the Tuberculosis Trials Consortium.
More informationChallenges in Therapeutic Drug Monitoring:
Challenges in Therapeutic Drug Monitoring: Focus on Vancomycin Pharmacodynamics and Pharmacokinetics Katherine Gallaga, PharmD PGY1 Pharmacy Practice Resident CHRISTUS Spohn Health System 1 Pharmacist
More informationAntimicrobial Reference Laboratory
Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2018 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB Guideline Ranges 2018 Aminoglycosides
More informationImproving Translation in TB Drug Development Through Quantitative Modeling. CPTR Workshop 2016, Washington DC
Improving Translation in TB Drug Development Through Quantitative Modeling Lessons from Recent Phase III TB Trials CPTR Workshop 2016, Washington DC Christian Lienhardt Global TB Programme WHO, Geneva,
More informationTreatment of tuberculosis and optimal dosing schedules
Thorax Online First, published on December 17, 2010 as 10.1136/thx.2010.148585 Review < Additional appendices are published online only. To view these files please visit the journal online (http://thorax.bmj.
More informationPreventing TB: Recent Research Results and Novel Short Course Therapy for LTBI
Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Constance A. Benson, M.D. Professor of Medicine Director, UCSD AntiViral Research Unit PI, CD4 Collaborative HIV Clinical
More informationClinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs Sturkenboom, Marieke Gemma Geertruida
University of Groningen Clinical pharmacology and therapeutic drug monitoring of first-line anti-tuberculosis drugs Sturkenboom, Marieke Gemma Geertruida IMPORTANT NOTE: You are advised to consult the
More informationPrinciples and practice of treating drug-sensitive TB
Principles and practice of treating drug-sensitive TB Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of
More informationTreatment and Monitoring
Treatment and Monitoring Disclosures We have no actual or potential conflicts of interest in relation to this presentations. We have no financial relationships to disclose. Learning Objectives After this
More informationAntimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018
Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationNew TB Medications. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention New TB Medications Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers
More informationPlasma Drug Activity Assay for Treatment Optimization in Tuberculosis Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2011, p. 5819 5825 Vol. 55, No. 12 0066-4804/11/$12.00 doi:10.1128/aac.05561-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Plasma
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationTB and Comorbidities Adriana Vasquez, MD April 12, 2018
TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:
More informationMultiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health
Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten
More informationPROBLEMS IN TX CASE STUDY. JB is a 42 yo BM who was admitted to
Why TB Drugs Fail Part 2 Why TB Drugs Fail OR How We Fail TB Drugs (and Tb Patients) 1 PROBLEMS IN TX FAILURE TO RESPOND TB MENINGITIS RENAL FAILURE HEPATITIS CAN T SWALLOW PILLS GI INTOLERANCE ADVERSE
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More informationDose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016
Dose Counting Exercise Elizabeth Foy, RN, BSN September 8, 2016 TB Nurse Case Management September 7-9, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Jessica Quintero, M.Ed., has the following disclosures
More informationTitle: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations
1 SUPPLEMENTARY MATERIALS 2 3 4 5 6 7 8 Title: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two Phase 2 clinical trials Authors: Radojka M. Savic,
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More informationTreatment: First Line Drugs TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS TREATMENT: GENERAL PRINCIPLES MECHANISM OF ACTION MID 27
TUBERCULOSIS TREATMENT: MEDICATIONS & REGIMENS Treatment: First Line Drugs 1. ISONIAZID = INH Bacteriocidal against dividing organisms Dose = 300mg = one pill = well absorbed Good CNS penetration Can be
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationIntroduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015
Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Initiation Phase Part 1 Ginny Dowell, RN, BSN February 4, 2015 Ginny Dowell RN, BSN has the following disclosures to make:
More informationCDC's Tuberculosis Trials Consortium
CDC's Tuberculosis Trials Consortium Kayla Laserson, Andrew Vernon, Erin Bliven, Neil Schluger, William Burman, Fred Gordin, Tim Sterling, Carol Dukes Hamilton, Debra Benator, Donna Conwell, Nancy Dianis,
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationCLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE
CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE Joseph K. Ritter, Ph.D. Assoc. Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@vcu.edu This self study module will reinforce the
More informationSurgery for MDR/XDR Tuberculosis
Surgery for MDR/XDR Tuberculosis John D. Mitchell, M.D. Davis Endowed Chair in Thoracic Surgery Professor and Chief, General Thoracic Surgery Department of Surgery University of Colorado School of Medicine
More informationTreatment of Tuberculosis
Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America Please note: An erratum has been published for this article. To view the erratum, please click here.
More informationEvidence review for Intermittent therapy for drug-susceptible TB: Questions addressed: intermittent therapy
Evidence review for Intermittent therapy for drug-susceptible TB: Dr. Dick Menzies Montreal Chest Institute, McGill University Montreal, Canada Questions addressed: intermittent therapy 1: Does intermittent
More informationMETHODS. higher doses of rifapentine when given once weekly with INH in the continuation phase of tuberculosis treatment in HIVseronegative
A Prospective, Randomized, Double-Blind Study of the Tolerability of Rifapentine 600, 900, and 1,200 mg Plus Isoniazid in the Continuation Phase of Tuberculosis Naomi N. Bock, Timothy R. Sterling, Carol
More informationMycobacterium tuberculosis
Mycobacterium tuberculosis Mycobacterium tuberculosis Ø aerobic Gram-positive bacillus Ø grow in the cell of host organism Ø the pathogen causes tuberculosis Ø asymptomatic and latent infections Ø can
More informationPatient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD
Patient History 1 The Role of Surgery in the Management of TB Reynard McDonald, MD & Paul Bolanowski, MD September 16, 2010 42 y/o AA male was initially diagnosed with pansensitive pulmonary TB in 1986
More informationPharmacodynamic indices in targeting therapy of critical infections
Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective
More informationHA Convention 2016 : Special Topic Session 3 May 2016
HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationA review of rifapentine for treating active and latent tuberculosis
tive & omes A review of rifapentine for treating active and latent tuberculosis Background: Nearly 1/3 of the world s population is infected with Mycobacterium tuberculosis (Mtb). Simple, effective treatment
More informationTherapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature
Long et al. BMC Infectious Diseases (2015) 15:327 DOI 10.1186/s12879-015-1093-7 CASE REPORT Open Access Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case
More informationThe treatment of patients with initial isoniazid resistance
The treatment of patients with initial isoniazid resistance 2011 INTERTB Meeting, St George s, London Patrick Phillips, MRC Clinical Trials Unit DA Mitchison, AJ Nunn. 21 st October 2011 Outline Background
More informationAntimicrobial Reference Laboratory
Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2016-17 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB UK Aminoglycosides Gentamicin
More informationEtiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition
Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis
More informationPHA Final Exam Fall 2001
PHA 5127 Final Exam Fall 2001 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /12 pts 2. /8 pts 3. /12 pts 4. /20 pts 5. /27 pts 6. /15
More informationWhat more is required to use rifamycin regimens to prevent TB in people living with HIV in resource constrained settings?
What more is required to use rifamycin regimens to prevent TB in people living with HIV in resource constrained settings? Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Priftin) Reference Number: CP.PMN.05 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Helath Plan Revision Log See Important Reminder at the end of this policy
More informationBlood Levels of Pyrazinamide in Children at Doses Administered Under the Revised National Tuberculosis Control Program
R E S E A R C H P A P E R Blood Levels of Pyrazinamide in Children at Doses Administered Under the Revised National Tuberculosis Control Program V ROY, P SAHNI, P GUPTA, *GR SETHI AND # A KHANNA From the
More informationPharmacokinetics and safety of Moxifloxacin: Preliminary results of a dose escalation study
Pharmacokinetics and safety of Moxifloxacin: Preliminary results of a dose escalation study A.D. Pranger 1, W.C.M. de Lange 2, R. van Altena 2, P. van der Harst 3, M.P. van den Berg 3, D.R.A. Uges 1, J.G.W.
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationTreatment of Tuberculosis
Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society
More information